RepliCel pursuing non-diluting grant funding

RepliCel Life Sciences

RepliCel Life Sciences (OTCQB:REPCF; TSX-V:RP; FRA:P6P2) has retained The FreeMind Group, an international firm that assists life science organizations in securing non-dilutive funding from granting agencies and private foundations.

“We have a number of strategic clinical and non-clinical projects which are ideally positioned for external collaborations and non-dilutive funding,” president and CEO, Lee Buckler, said in a statement.

These include basic research, manufacturing optimization, product development, and clinical objectives, which have the potential to create significant intellectual property and shareholder value.

“FreeMind has a proven track record and commitment to success-based remuneration that convinces us they will bring significant value to our programs,” he added.

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.